The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Safety and efficacy of surovatamig in patients with R/R NHL: results from a Phase I trial
In this video, Ranjit Nair, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the promising results of a Phase I study evaluating the safety and efficacy of surovatamig (AZD0486), a CD19-targeting bispecific T-cell engager, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Dr Nair shares results from the diffuse large B-cell lymphoma (DLBCL) cohort, stating that the agent appears to elicit deep and durable responses, with manageable side effects. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
